Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RESTORE-1: Inhaled Flecainide for AF Cardioversion
NCT05039359Phase 3Terminated
- Sponsor
- InCarda Therapeutics
- Start
- Apr 2022
- Primary completion
- May 2023
- Modality
- Small Molecules
- Countries
- 6
01
Overview
A Phase 3 trial of flecainide acetate inhalation solution in Atrial fibrillation (AFib), sponsored by InCarda Therapeutics. Started Apr 2022; status: terminated.
02
Drugs
flecainide acetate inhalation solution
03
Conditions
Atrial fibrillation (AFib)
Beyond the preview
Go deeper on NCT05039359.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05039359.